{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:22:33Z","timestamp":1786116153541,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20308"],"award-info":[{"award-number":["U22A20308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Research Funds of the State Key Laboratory of Ophthalmology","award":["2025QNJS21"],"award-info":[{"award-number":["2025QNJS21"]}]},{"name":"the Research Funds of the State Key Laboratory of Ophthalmology, the Open Research Funds of the State Key Laboratory of Ophthalmology","award":["2025QZLH03"],"award-info":[{"award-number":["2025QZLH03"]}]},{"name":"the Guangdong Basic Research Center of Excellence for Major Blinding Eye Diseases Prevention and Treatment","award":["SJCQN-004"],"award-info":[{"award-number":["SJCQN-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-026-03934-9","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:04:33Z","timestamp":1783674273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phosphorylated TYK2 orchestrates the pathogenic program of CD4\u2009+\u2009T cells in the development of CNS autoimmunity"],"prefix":"10.1186","volume":"23","author":[{"given":"Hao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"3934_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2013.08.003","volume":"50","author":"WP Chong","year":"2014","unstructured":"Chong WP, Horai R, Mattapallil MJ, Silver PB, Chen J, Zhou R, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun. 2014;50:12\u201322.","journal-title":"J Autoimmun"},{"issue":"9","key":"3934_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623\u201335.","journal-title":"Nat Rev Immunol"},{"key":"3934_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1073\/pnas.2109548118","volume":"118","author":"JK Choi","year":"2021","unstructured":"Choi JK, Yu CR, Bing SJ, Jittayasothorn Y, Mattapallil MJ, Kang M, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. Proc Natl Acad Sci USA. 2021;118:47.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3934_CR4","doi-asserted-by":"publisher","first-page":"869046","DOI":"10.3389\/fopht.2022.869046","volume":"2","author":"JV Forrester","year":"2022","unstructured":"Forrester JV, M\u00f6lzer C, Kuffova L. Immune privilege furnishes a niche for latent infection. Front Ophthalmol. 2022;2:869046.","journal-title":"Front Ophthalmol"},{"key":"3934_CR5","doi-asserted-by":"crossref","unstructured":"Wu C, Jiang M, Yang X, Liu Y, Huang B, Guo Y, et al. ANKRD55 is a key regulator of T cell inflammation in multiple sclerosis. J Clin Investig. 2025;135(20):e195214.","DOI":"10.1172\/JCI195214"},{"issue":"1","key":"3934_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12974-024-03270-w","volume":"21","author":"S Angiari","year":"2024","unstructured":"Angiari S, Carlucci T, Budui SL, Bach SD, Dusi S, Walter J, et al. Coenzyme A fueling with pantethine limits autoreactive T cell pathogenicity in experimental neuroinflammation. J Neuroinflamm. 2024;21(1):287.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"3934_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2025.11.035","volume":"189","author":"C Zou","year":"2026","unstructured":"Zou C, Li P, Li B, Sparwasser T, Yuan J. Next steps in regulatory T cells: biology and clinical application. Cell. 2026;189(1):6\u201322.","journal-title":"Cell"},{"issue":"1","key":"3934_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez R, P\u00e9rez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56\u201364.","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"3934_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, Kostov B, Perez-Alvarez R, Brito-Zer\u00f3n P, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Exp Opin Drug Saf. 2017;16(11):1255\u201371.","journal-title":"Exp Opin Drug Saf"},{"issue":"2","key":"3934_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","volume":"99","author":"LCP Tavares","year":"2024","unstructured":"Tavares LCP, Caetano LVN, Ianhez M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. An Bras Dermatol. 2024;99(2):259\u201368.","journal-title":"An Bras Dermatol"},{"key":"3934_CR11","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.preteyeres.2023.101216","volume":"97","author":"Z Zhong","year":"2023","unstructured":"Zhong Z, Su G, Yang P. Risk factors, clinical features and treatment of Beh\u00e7et\u2019s disease uveitis. Prog Retin Eye Res. 2023;97:101216.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"3934_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","volume":"20","author":"E Morand","year":"2024","unstructured":"Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2024;20(4):232\u201340.","journal-title":"Nat Rev Rheumatol"},{"key":"3934_CR13","doi-asserted-by":"publisher","first-page":"104840","DOI":"10.1016\/j.ebiom.2023.104840","volume":"97","author":"LT Jensen","year":"2023","unstructured":"Jensen LT, Attfield KE, Feldmann M, Fugger L. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. EBioMedicine. 2023;97:104840.","journal-title":"EBioMedicine"},{"issue":"6","key":"3934_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/bjd\/ljaf293","volume":"193","author":"S Wasserer","year":"2025","unstructured":"Wasserer S, Seiringer P, Kurzen N, Jargosch M, Eigemann J, Aydin G, et al. Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus. Br J Dermatol. 2025;193(6):1192\u2013203.","journal-title":"Br J Dermatol"},{"issue":"4","key":"3934_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira M, Puig L, Torres T. JAk inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341\u201352.","journal-title":"Drugs"},{"key":"3934_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski","year":"2016","unstructured":"Roskoski R. Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784\u2013803.","journal-title":"Pharmacol Res"},{"issue":"11","key":"3934_CR17","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.autrev.2024.103649","volume":"23","author":"C Ramakrishna","year":"2024","unstructured":"Ramakrishna C, Mason A, Edwards CJ. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun rev. 2024;23(11):103649.","journal-title":"Autoimmun rev"},{"issue":"3","key":"3934_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.70146","volume":"119","author":"H Duan","year":"2026","unstructured":"Duan H, Jiang C, Zhang B, Meng H, Zhou W, Yan W, et al. Risk of malignancies and major adverse cardiovascular events related to JAK inhibitors in rheumatoid arthritis: a meta-analysis. Clin Pharmacol Ther. 2026;119(3):598\u2013607.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3934_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discovery. 2017;16(12):843\u201362.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"3934_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"363","key":"3934_CR21","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149.","journal-title":"Sci Transl Med"},{"issue":"2","key":"3934_CR22","doi-asserted-by":"publisher","first-page":"e20200425","DOI":"10.1590\/1678-4685-gmb-2020-0425","volume":"44","author":"FM Pellenz","year":"2021","unstructured":"Pellenz FM, Dieter C, Lemos NE, Bauer AC, Souza BM, Crispim D. Association of TYK2 polymorphisms with autoimmune diseases: a comprehensive and updated systematic review with meta-analysis. Genet Mol biology. 2021;44(2):e20200425.","journal-title":"Genet Mol biology"},{"key":"3934_CR23","doi-asserted-by":"publisher","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","volume":"189","author":"R Roskoski","year":"2023","unstructured":"Roskoski R. Jr. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;189:106642.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3934_CR24","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","volume":"149","author":"IM Catlett","year":"2022","unstructured":"Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149(6):2010\u2013e208.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3934_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","volume":"161","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, et al. Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials. JAMA dermatology. 2025;161(1):56\u201366.","journal-title":"JAMA dermatology"},{"key":"3934_CR26","doi-asserted-by":"crossref","unstructured":"Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (Hoboken, NJ). 2023;75(2):242\u201352.","DOI":"10.1002\/art.42391"},{"issue":"11","key":"3934_CR27","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.4049\/jimmunol.0902740","volume":"183","author":"A Oyamada","year":"2009","unstructured":"Oyamada A, Ikebe H, Itsumi M, Saiwai H, Okada S, Shimoda K, et al. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J Immunol (Baltimore Md: 1950). 2009;183(11):7539\u201346.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"issue":"13","key":"3934_CR28","doi-asserted-by":"publisher","first-page":"e2422172122","DOI":"10.1073\/pnas.2422172122","volume":"122","author":"TP Molitor","year":"2025","unstructured":"Molitor TP, Hayashi G, Lin MY, Dunn CJ, Peterson NG, Poston RG, et al. Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulator. Proc Natl Acad Sci USA. 2025;122(13):e2422172122.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"3934_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cyto.2015.01.030","volume":"75","author":"L Sun","year":"2015","unstructured":"Sun L, He C, Nair L, Yeung J, Egwuagu CE. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine. 2015;75(2):249\u201355.","journal-title":"Cytokine"},{"issue":"2","key":"3934_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233\u201340.","journal-title":"J Exp Med"},{"issue":"9","key":"3934_CR31","doi-asserted-by":"publisher","first-page":"102303","DOI":"10.1016\/j.xcrm.2025.102303","volume":"6","author":"K Tuomela","year":"2025","unstructured":"Tuomela K, Garcia RV, Boardman DA, Tavakoli P, Ancheta-Schmit M, Sham HP, et al. TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation. Cell Rep Med. 2025;6(9):102303.","journal-title":"Cell Rep Med"},{"issue":"11","key":"3934_CR32","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/02713680500263606","volume":"30","author":"P Yang","year":"2005","unstructured":"Yang P, Zhang Z, Zhou H, Li B, Huang X, Gao Y, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res. 2005;30(11):943\u20138.","journal-title":"Curr Eye Res"},{"issue":"3","key":"3934_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/bjophthalmol-2020-316256","volume":"105","author":"T Hao","year":"2021","unstructured":"Hao T, Yang LI, Li B, Chen X, Li D, Liu X. Epidemiology of 2000 Chinese uveitis patients from Northeast China. Br J Ophthalmol. 2021;105(3):317\u201321.","journal-title":"Br J Ophthalmol"},{"key":"3934_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ajo.2021.03.036","volume":"228","author":"Group SoUNSW","year":"2021","unstructured":"Group SoUNSW. Classification criteria for vogt-koyanagi-harada disease. Am J Ophthalmol. 2021;228:205\u201311.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"3934_CR35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1167\/iovs.07-0868","volume":"49","author":"LM Cortes","year":"2008","unstructured":"Cortes LM, Mattapallil MJ, Silver PB, Donoso LA, Liou GI, Zhu W, et al. Repertoire analysis and new pathogenic epitopes of IRBP in C57BL\/6 (H-2b) and B10.RIII (H-2r) mice. Invest Ophthalmol Vis Sci. 2008;49(5):1946\u201356.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3934_CR36","first-page":"211","volume":"1899","author":"J Chen","year":"2019","unstructured":"Chen J, Caspi RR. Clinical and functional evaluation of ocular inflammatory disease using the model of experimental autoimmune uveitis. (Clifton NJ). 2019;1899:211\u201327. Methods in molecular biology.","journal-title":"(Clifton NJ)"},{"issue":"6","key":"3934_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/1352458511398885","volume":"17","author":"D Baker","year":"2011","unstructured":"Baker D, Gerritsen W, Rundle J, Amor S. Critical appraisal of animal models of multiple sclerosis. Mult Scler. 2011;17(6):647\u201357.","journal-title":"Mult Scler"},{"key":"3934_CR38","doi-asserted-by":"publisher","first-page":"0662","DOI":"10.1126\/science.adv4635","volume":"8","author":"L Yang","year":"2025","unstructured":"Yang L, Han X, Wang M, Zhang X, Wang L, Xu N, et al. Early growth response gene 1 benefits autoimmune disease by promoting regulatory T cell differentiation as a regulator of foxp3. Res (Washington DC). 2025;8:0662.","journal-title":"Res (Washington DC)"},{"issue":"1","key":"3934_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12974-022-02477-z","volume":"19","author":"J Huang","year":"2022","unstructured":"Huang J, Li Z, Hu Y, Li Z, Xie Y, Huang H, et al. Melatonin, an endogenous hormone, modulates Th17 cells via the reactive-oxygen species\/TXNIP\/HIF-1\u03b1 axis to alleviate autoimmune uveitis. J Neuroinflamm. 2022;19(1):124.","journal-title":"J Neuroinflamm"},{"issue":"1\u20132","key":"3934_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","volume":"333","author":"A Rostami","year":"2013","unstructured":"Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci. 2013;333(1\u20132):76\u201387.","journal-title":"J Neurol Sci"},{"issue":"815","key":"3934_CR41","doi-asserted-by":"publisher","first-page":"eadp5802","DOI":"10.1126\/scitranslmed.adp5802","volume":"17","author":"JF Varghese","year":"2025","unstructured":"Varghese JF, Fujiwara M, Ajay AK, Garo LP, Cannon A, Kadowaki-Saga R, et al. Type I interferon limits central nervous system autoimmunity by modulating the microRNA-21-FOXO1 axis in pathogenic T helper 17 cells. Sci Transl Med. 2025;17(815):eadp5802.","journal-title":"Sci Transl Med"},{"issue":"2","key":"3934_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","volume":"155","author":"S Samra","year":"2025","unstructured":"Samra S, Bergerson JRE, Freeman AF, Turvey SE. JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity. J Allergy Clin Immunol. 2025;155(2):357\u201367.","journal-title":"J Allergy Clin Immunol"},{"key":"3934_CR43","doi-asserted-by":"publisher","first-page":"114760","DOI":"10.1016\/j.bcp.2021.114760","volume":"193","author":"HT Tzeng","year":"2021","unstructured":"Tzeng HT, Chyuan IT, Lai JH. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: a focus on molecular mechanisms and therapeutic potential. Biochem Pharmacol. 2021;193:114760.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"3934_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521\u201346.","journal-title":"Drugs"},{"issue":"9","key":"3934_CR45","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1002\/jcp.29593","volume":"235","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Javadian M, Babaloo Z, Baradaran B. Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases. J Cell Physiol. 2020;235(9):5903\u201324.","journal-title":"J Cell Physiol"},{"key":"3934_CR46","doi-asserted-by":"crossref","unstructured":"Jones DM, Read KA, Oestreich KJ. Dynamic roles for IL-2-STAT5 signaling in effector and regulatory CD4(+) T cell populations. J Immunol (Baltimore, Md: 1950). 2020;205(7):1721-30.","DOI":"10.4049\/jimmunol.2000612"},{"issue":"2","key":"3934_CR47","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","volume":"30","author":"A Yu","year":"2009","unstructured":"Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity. 2009;30(2):204\u201317.","journal-title":"Immunity"},{"issue":"1","key":"3934_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target therapy. 2021;6(1):402.","journal-title":"Signal Transduct Target therapy"},{"issue":"11","key":"3934_CR49","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/art.42547","volume":"75","author":"A Virtanen","year":"2023","unstructured":"Virtanen A, Palmroth M, Liukkonen S, Kurttila A, Haikarainen T, Isom\u00e4ki P, et al. Differences in JAK isoform selectivity among different types of JAK inhibitors evaluated for rheumatic diseases through in vitro profiling. Arthritis Rheumatol (Hoboken NJ). 2023;75(11):2054\u201361.","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"issue":"10","key":"3934_CR50","doi-asserted-by":"publisher","first-page":"e2400004","DOI":"10.1002\/advs.202400004","volume":"12","author":"W Zhu","year":"2025","unstructured":"Zhu W, Chen G, Xiao Z, Wang M, Li Z, Shi Y, et al. Circadian rhythm disruption exacerbates autoimmune uveitis: the essential role of PER1 in treg cell metabolic support for stability and function. Adv Sci (Weinh). 2025;12(10):e2400004.","journal-title":"Adv Sci (Weinh)"},{"key":"3934_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jaut.2019.02.006","volume":"100","author":"SJ Bing","year":"2019","unstructured":"Bing SJ, Shemesh I, Chong WP, Horai R, Jittayasothorn Y, Silver PB, et al. AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells. J Autoimmun. 2019;100:52\u201361.","journal-title":"J Autoimmun"},{"issue":"1","key":"3934_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.13519","volume":"171","author":"C Keohane","year":"2015","unstructured":"Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171(1):60\u201373.","journal-title":"Br J Haematol"},{"issue":"2","key":"3934_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/leu.2013.296","volume":"28","author":"M Massa","year":"2014","unstructured":"Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28(2):449\u201351.","journal-title":"Leukemia"},{"issue":"6","key":"3934_CR54","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1093\/rheumatology\/keaf046","volume":"64","author":"X Xing","year":"2025","unstructured":"Xing X, Li Y, Liu Q, Wang N, Zhang K, Mo W, et al. Tofacitinib treatment for active dermatomyositis and anti-synthetase syndrome: a prospective cohort pilot study. Rheumatology (Oxford). 2025;64(6):3756\u201366.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3934_CR55","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1136\/annrheumdis-2019-216576","volume":"80","author":"A Meyer","year":"2021","unstructured":"Meyer A, Wittekind PS, Kotschenreuther K, Schiller J, von Tresckow J, Haak TH, et al. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors. Ann Rheum Dis. 2021;80(12):e196.","journal-title":"Ann Rheum Dis"},{"issue":"41","key":"3934_CR56","doi-asserted-by":"publisher","first-page":"e2517132122","DOI":"10.1073\/pnas.2517132122","volume":"122","author":"J Zhao","year":"2025","unstructured":"Zhao J, Dainichi T, Guichard V, Zhang Y, Shirley S, Le\u00e3o FB, et al. A time-gated PKA-CREB signaling circuit licenses IL-12 responsiveness and Th1 fate in CD4(+) T cells. Proc Natl Acad Sci USA. 2025;122(41):e2517132122.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6587","key":"3934_CR57","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/382174a0","volume":"382","author":"MH Kaplan","year":"1996","unstructured":"Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature. 1996;382(6587):174\u20137.","journal-title":"Nature"},{"issue":"6587","key":"3934_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/382171a0","volume":"382","author":"WE Thierfelder","year":"1996","unstructured":"Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996;382(6587):171\u20134.","journal-title":"Nature"},{"key":"3934_CR59","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.2147\/JIR.S522927","volume":"18","author":"M Si","year":"2025","unstructured":"Si M, Wang Y, Wu H, Huang Y, Ma M, Su K, et al. Jianpi Lishi Jiedu Decoction (JLJD) Inhibit Th17 Cell Differentiation via the Jak\/Stat3\/ROR\u03b3t Pathway in Colorectal Adenomas. J Inflamm Res. 2025;18:11479\u201392.","journal-title":"J Inflamm Res"},{"issue":"7446","key":"3934_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature11981","volume":"496","author":"N Yosef","year":"2013","unstructured":"Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature. 2013;496(7446):461\u20138.","journal-title":"Nature"},{"issue":"1","key":"3934_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36\u201349.","journal-title":"Nat Rev Immunol"},{"key":"3934_CR62","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","volume":"23","author":"AN Theofilopoulos","year":"2005","unstructured":"Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha\/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307\u201336.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"3934_CR63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1535370218824547","volume":"244","author":"M Larosa","year":"2019","unstructured":"Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, et al. IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus. Exp Biol Med (Maywood). 2019;244(1):42\u201351.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"11","key":"3934_CR64","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.4049\/jimmunol.1502043","volume":"196","author":"C Ding","year":"2016","unstructured":"Ding C, Chen X, Dascani P, Hu X, Bolli R, Zhang HG, et al. STAT3 signaling in B cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus. J Immunol (Baltimore Md: 1950). 2016;196(11):4477\u201386.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"issue":"9","key":"3934_CR65","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/ijbs.41852","volume":"16","author":"C Yang","year":"2020","unstructured":"Yang C, Mai H, Peng J, Zhou B, Hou J, Jiang D. STAT4: an immunoregulator contributing to diverse human diseases. Int J Biol Sci. 2020;16(9):1575\u201385.","journal-title":"Int J Biol Sci"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-026-03934-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-026-03934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-026-03934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T08:03:39Z","timestamp":1786003419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-026-03934-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3934"],"URL":"https:\/\/doi.org\/10.1186\/s12974-026-03934-9","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee of the Zhongshan Ophthalmic Center, Sun Yat-sen University, and adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research (Approval No. Z2026017). We also express our gratitude to all the patients for providing the samples. All participants in this study provided written informed consent. The experimental protocols involving human subjects were reviewed and approved by the Ethics Committee of Zhongshan Ophthalmic Center, Sun Yat-sen University (Approval no. 2020KYPJ104).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"269"}}